Inovio Pharmaceuticals Reports 2015 Second Quarter Results; Conference Call Will Discuss New Cancer Partnership

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Inovio Pharmaceuticals Reports 2015 Second Quarter Results; Conference Call Will Discuss New Cancer Partnership

Inovio Pharmaceuticals (INO) Bullish Stance Reiterated at Stifel

August 10, 2015 11:34 AM EDT

Stifel analyst Thomas Shrader reiterated a Buy rating and $19 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the company announced Q2 results and a broad partnership with MedImmune to develop INO-3112 in combination with MedImmunes collection of IO molecules.

Shrader said he likes the deal.... More

Inovio Pharmaceuticals (INO) Overweight Rating, $31 PT Reiterated at Piper Jaffray Amid AstraZeneca Deal

August 10, 2015 11:19 AM EDT

Piper Jaffray analyst Charles Duncan reiterated his Overweight rating and $31 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the company announced 2Q financials and a partnership with AstraZeneca worth up to $700M ($27.5M upfront + potential development, regulatory, and commercialization milestones) plus tiered double... More

Inovio Pharma (INO) Tops Q2 EPS by 4c

August 10, 2015 6:53 AM EDT

Inovio Pharma (NASDAQ: INO) reported Q2 EPS of ($0.09), $0.04 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $5.3 million versus the consensus estimate of $5.52 million.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.

... More